Fibromyalgia – Living with Chronic Pain
Imagine living life with persistent pain that spreads throughout your body and feeling constantly drained. Fibromyalgia is a common...
Can we improve how we capture data in psychedelic trials?
Read our white paper to find out more Last month we attended the 2023 CDISC Europe Interchange where MAC Principal SAS Programmer, Martyn...
Clinical research continues to bring hope to Parkinson’s patients
Parkinson's disease (PD) is a progressive movement disorder of the nervous system. Like a fingerprint, disease presentation is different...
Raising awareness of sickle cell disease
As part of Rare Disease Day 2023, we want to highlight the work we are doing in Sickle cell disease. Sickle cell disease is the name for...
First participant dosed in first-in-human Phase I clinical trial of DMT-based drug
We are excited to share that our Early Phase Unit in Manchester dosed the first participant in Small Pharma’s first-in-human Phase I...
What can we do about the placebo response in clinical trials?
The placebo response or the placebo effect. We hear about it a lot, but what happens in practise? Let’s unravel it by understanding what...
Our expert weighs in on the relationship between alcohol and ED
At MAC we have expertise in a wide range of different areas including Men and Women’s Health. One of these areas we have active studies...
Could psychedelic research be a promising new step in treating mental health disorders?
The next generation of treatment? Could psychedelic research be a promising new step in treating mental health disorders like depression,...
New Alzheimer's Drug to Enter Clinical Trials
A new drug developed by Lancaster University which may help to prevent the early stages of Alzheimer’s disease is to enter clinical...
